v3.26.1
Condensed Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Non-controlling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024 $ 1,158          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net loss attributable to redeemable noncontrolling interests (1,350)          
Redeemable noncontrolling interests, ending balance at Mar. 31, 2025 (192)          
Balance, beginning of period at Dec. 31, 2024 1,521,199 $ 1,428 $ 754,415 $ 9,737 $ 365,796 $ 389,823
Balance, beginning of period (in shares) at Dec. 31, 2024   142,747,818        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. 41,383       41,383  
Net income attributable to noncontrolling interests 18,932         18,932
Other comprehensive income (5,809)     (5,809)    
Distributions to noncontrolling interests (19,239)         (19,239)
Vesting of restricted stock unit awards (in shares)   289,946        
Vesting of restricted stock unit awards (1,061) $ 2 (1,063)      
Equity-based compensation 9,263   9,263      
Balance, ending of period at Mar. 31, 2025 1,564,668 $ 1,430 762,615 3,928 407,179 389,516
Balance, ending of period (in shares) at Mar. 31, 2025   143,037,764        
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024 1,158          
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025 (1,751)          
Balance, beginning of period at Dec. 31, 2024 1,521,199 $ 1,428 754,415 9,737 365,796 389,823
Balance, beginning of period (in shares) at Dec. 31, 2024   142,747,818        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. 114,333          
Other comprehensive income (10,133)          
Balance, ending of period at Jun. 30, 2025 1,648,126 $ 1,431 773,422 (396) 480,129 393,540
Balance, ending of period (in shares) at Jun. 30, 2025   143,098,506        
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2025 (192)          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net loss attributable to redeemable noncontrolling interests (1,559)          
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025 (1,751)          
Balance, beginning of period at Mar. 31, 2025 1,564,668 $ 1,430 762,615 3,928 407,179 389,516
Balance, beginning of period (in shares) at Mar. 31, 2025   143,037,764        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. 72,950       72,950  
Net income attributable to noncontrolling interests 24,310         24,310
Other comprehensive income (4,324)     (4,324)    
Distributions to noncontrolling interests (20,286)         (20,286)
Issuance of common stock (in shares)   7,553        
Vesting of restricted stock unit awards (in shares)   66,306        
Vesting of restricted stock unit awards (438) $ 1 (439)      
Forfeitures of restricted stock awards (in shares)   (13,117)        
Equity-based compensation 11,246   11,246      
Balance, ending of period at Jun. 30, 2025 1,648,126 $ 1,431 773,422 (396) 480,129 393,540
Balance, ending of period (in shares) at Jun. 30, 2025   143,098,506        
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2025 [1] (1,250)          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net loss attributable to redeemable noncontrolling interests (2,513)          
Redeemable noncontrolling interests, ending balance at Mar. 31, 2026 (3,763)          
Balance, beginning of period at Dec. 31, 2025 $ 1,686,214 [1] $ 1,429 788,472 (3,610) 501,607 398,316
Balance, beginning of period (in shares) at Dec. 31, 2025 142,864,171 142,864,171        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. $ 39,850       39,850  
Net income attributable to noncontrolling interests 21,151         21,151
Other comprehensive income 1,164     1,164    
Distributions to noncontrolling interests (21,314)         (21,314)
Vesting of restricted stock unit awards (in shares)   275,928        
Vesting of restricted stock unit awards (1,014) $ 2 (1,016)      
Forfeitures of restricted stock awards (in shares)   (6,274)        
Equity-based compensation 8,929   8,929      
Balance, ending of period at Mar. 31, 2026 1,734,980 $ 1,431 796,385 (2,446) 541,457 398,153
Balance, ending of period (in shares) at Mar. 31, 2026   143,133,825        
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2025 [1] (1,250)          
Redeemable noncontrolling interests, ending balance at Jun. 30, 2026 [1] (4,658)          
Balance, beginning of period at Dec. 31, 2025 $ 1,686,214 [1] $ 1,429 788,472 (3,610) 501,607 398,316
Balance, beginning of period (in shares) at Dec. 31, 2025 142,864,171 142,864,171        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. $ 56,749          
Other comprehensive income 2,972          
Balance, ending of period at Jun. 30, 2026 $ 1,746,062 [1] $ 1,419 791,411 (638) 558,356 395,514
Balance, ending of period (in shares) at Jun. 30, 2026 141,910,898 141,910,898        
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2026 $ (3,763)          
Increase (Decrease) in Temporary Equity [Roll Forward]            
Net loss attributable to redeemable noncontrolling interests (895)          
Redeemable noncontrolling interests, ending balance at Jun. 30, 2026 [1] (4,658)          
Balance, beginning of period at Mar. 31, 2026 1,734,980 $ 1,431 796,385 (2,446) 541,457 398,153
Balance, beginning of period (in shares) at Mar. 31, 2026   143,133,825        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income attributable to Ardent Health, Inc. 16,899       16,899  
Net income attributable to noncontrolling interests 18,685         18,685
Other comprehensive income 1,808     1,808    
Proceeds from the sale of noncontrolling interest 2,723   1,218     1,505
Distributions to noncontrolling interests (22,829)         (22,829)
Repurchase of common stock (in shares)   (1,397,765)        
Repurchase of common stock (13,160) $ (14) (13,146)      
Vesting of restricted stock unit awards (in shares)   640,199        
Vesting of restricted stock unit awards (991) $ 7 (998)      
Forfeitures of restricted stock awards (in shares)   (465,361)        
Forfeiture of restricted stock awards (5) $ (5)        
Equity-based compensation 7,952   7,952      
Balance, ending of period at Jun. 30, 2026 $ 1,746,062 [1] $ 1,419 $ 791,411 $ (638) $ 558,356 $ 395,514
Balance, ending of period (in shares) at Jun. 30, 2026 141,910,898 141,910,898        
[1] As of June 30, 2026 and December 31, 2025, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of $331.2
million and $335.1 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.